100% SVR IN IL28B CC PATIENTS TREATED WITH 12 WEEKS OF TELAPREVIR, PEGINTERFERON AND RIBAVIRIN IN THE PROVE2 TRIAL

被引：30
|
作者：
Bronowicki, J-P [1 ]
Hezode, C. [2 ]
Bengtsson, L. [3 ]
Pol, S. [4 ]
Bourliere, M. [5 ]
Serfaty, L. [6 ]
de Ledinghen, V. [7 ]
Tran, A. [8 ]
Benhamou, Y. [9 ]
Grange, J-D [10 ]
Mathurin, P. [11 ]
Marcellin, P. [12 ]
Trepo, C. [13 ]
Zarski, J-P [14 ]
Seepersaud, S. [3 ]
Kelliher, K. [3 ]
Botfield, M. [3 ]
Pawlotsky, J-M [2 ]
机构：
[1] CHU Nancy, INSERM, U954, Nancy, France
[2] Hop Henri Mondor, F-94010 Creteil, France
[3] Vertex Pharmaceut Inc, Cambridge, MA USA
[4] Hop Cochin, F-75674 Paris, France
[5] Hop St Joseph, Marseille, France
[6] Hop St Antoine, F-75571 Paris, France
[7] CHU Bordeaux, Bordeaux, France
[8] CHU Nice, Nice, France
[9] Hop La Pitie Salpetriere, Paris, France
[10] Hop Tenon, F-75970 Paris, France
[11] CHU Lille, F-59037 Lille, France
[12] Hop Beaujon, Clichy, France
[13] CHU Lyon, Lyon, France
[14] CHU Grenoble, F-38043 Grenoble, France
来源：
JOURNAL OF HEPATOLOGY | 2012年 / 56卷
关键词：
D O I：
10.1016/S0168-8278(12)61106-4
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1094
引用
收藏
页码：S430 / S431
页数：2
相关论文
共 50 条
  • [21] TELAPREVIR-BASED REGIMENS SUBSTANTIALLY IMPROVED SVR RATES ACROSS ALL IL28B GENOTYPES IN THE ADVANCE TRIAL
    Jacobson, Ira M.
    Catlett, Ian M.
    Marcellin, Patrick
    Bzowej, Natalie H.
    Muir, Andrew J.
    Adda, Nathalie
    Seepersaud, Shelia
    Ramachandran, Ravi
    Sussky, Katherine
    Bengtsson, Leif
    George, Shelley
    Kauffman, Robert S.
    Botfield, Martyn C.
    GASTROENTEROLOGY, 2011, 140 (05) : S145 - S145
  • [22] IL28B polymorphism and virological response during 12 weeks of pegIFN and ribavirin treatment in Polish chronic hepatitis C patients
    Swiatek, B.
    Januszkiewicz-Lewandowska, D.
    Wysocki, J.
    Mozer-Lisewska, I.
    Kowala-Piaskowska, A.
    Bereszynska, I.
    Rembowska, J.
    Nowak, J.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2013, 42 : S132 - S132
  • [23] IL28B polymorphism and virological responseduring 12 weeks of pegylated interferon and ribavirin treatment in Polish chronic hepatitis C patients
    Swiatek, B.
    Januszkiewicz, D.
    Rembowska, J.
    Bereszynska, I.
    Kowala-Piaskowska, A.
    Mozer-Lisewska, I.
    Wysocki, J.
    Nowak, J.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2014, 21 : 313 - 313
  • [24] NON RESPONSE TO PEGINTERFERON ALFA AND RIBAVIRIN IN IL28B CC & CT PATIENTS CAN BE OVERCOME BY HIGH DOSE CONTINUOUS INTERFERON ALFA-2B ADMINISTRATION IN COMBINATION WITH RIBAVIRIN FOR CHRONIC HEPATITIS C
    Roomer, Robert
    de Knegt, Robert J.
    Bergmann, Jilling F.
    Scherer, Rachael M.
    Van Antwerp, Bill
    Lande, Jeff
    Grovender, Eric
    Janssen, Harry L.
    Boonstra, Andre
    HEPATOLOGY, 2010, 52 (04) : 880A - 880A
  • [25] VX-222/TELAPREVIR IN COMBINATION WITH PEGINTERFERON-ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 1 HCV PATIENTS TREATED FOR 12 WEEKS: ZENITH STUDY, SVR12 INTERIM ANALYSIS
    Nelson, David R.
    Gane, Edward J.
    Jacobson, Ira M.
    Di Bisceglie, Adrian M.
    Alves, Katia
    Koziel, Margaret J.
    De Souza, Cynthia
    Kieffer, Tara L.
    George, Shelley
    Rosario, Maria
    Kauffman, Robert S.
    Sulkowski, Mark S.
    HEPATOLOGY, 2011, 54 : 1435A - 1435A
  • [26] Cirrhosis and Rapid Virological Response to Peginterferon Plus Ribavirin Determine Treatment Outcome in HCV-1 IL28B rs12979860 CC Patients
    Aghemo, Alessio
    Degasperi, Elisabetta
    Rumi, Maria Grazia
    Galmozzi, Enrico
    Valenti, Luca
    De Francesco, Raffaele
    De Nicola, Stella
    Cheroni, Cristina
    Grassi, Eleonora
    Colombo, Andmassimo
    BIOMED RESEARCH INTERNATIONAL, 2013, 2013
  • [27] Telaprevir in Combination with Peginterferon and Ribavirin In Genotype 1 HCV Treatment-Naive Patients, Prior Relapsers and Prior Non-Responders: Pooled Analysis Of PROVE 1, PROVE2, PROVE3 and Study 107
    Shiffman, Mitchell
    Berg, Thomas
    Muir, Andrew
    McHutchison, John
    Pawlotsky, Jean-Michel
    Zeuzem, Stefan
    Bengtsson, Leif
    Adda, Nathalie
    George, Shelley
    Kauffman, Robert
    Poordad, Fred
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S102 - S102
  • [28] IMPROVED SUSTAINED VIROLOGIC RESPONSE (SVR) RATES IN "DIFFICULT-TO-CURE" PATIENTS TREATED WITH TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN: AN ANALYSIS FROM THE PROVE3 STUDY
    Manns, M. P.
    Muir, A. J.
    Adda, N.
    McHutchison, J. G.
    Terrault, N.
    Bengtsson, L.
    George, S.
    Di Bisceglie, A. M.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S115 - S115
  • [29] FACTORS INVOLVED IN SUSTAINED VIRAL RESPONSE (SVR) ACHIEVEMENT IN PATIENTS WITH FAVORABLE IL28B CC GENOTYPE IN HEPATITIS C
    Maraver, M.
    Rojas, L.
    Ampuero, J.
    Rojas, A.
    Sola, R.
    Moreno-Otero, R.
    Andrade, R.
    Diago, M.
    Salmeron, J.
    Rodrigo, L.
    Garcia-Samaniego, J.
    Calleja, J. L.
    Pons, J. A.
    Cano, C.
    Millan, M.
    Millan, R.
    Romero-Gomez, M.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S353 - S354
  • [30] Evaluation of viral variants during a Phase 2 study (PROVE2) of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive HCV genotype I-infected patients
    Kieffer, Tara
    Zhou, Yi
    Zhang, Eileen
    Marcial, Michelle
    Byrn, Randal
    Pfeiffer, Thomas
    Miller, Janice
    Tigges, Ann
    Bartels, Doug
    Kwong, Ann
    Ferenci, Peter
    Dusheiko, Geoffrey
    Zeuzem, Stefan
    Pawlotsky, Jean-Michel
    HEPATOLOGY, 2007, 46 (04) : 862A - 862A
12345